This blog explores the vital role of breast cancer clinical trials in providing patients with early access to innovative treatments and offering key insights that drive medical progress. At Lambda Therapeutic Research, we’re honored to partner with global biotech and pharmaceutical leaders to support these life-changing studies, working together for a future with better outcomes for breast cancer patients.
Breast Cancer Awareness Month
October is Breast Cancer Awareness Month, an annual campaign dedicated to raising awareness and reflecting on the progress in breast cancer research, prevention, and treatment. Breast cancer remains the most common cancer worldwide, with approximately 2.3 million new cases diagnosed each year. In the United States alone, 1 in 8 women will face a breast cancer diagnosis in her lifetime. Despite these staggering statistics, advances in early detection and treatment are transforming the outlook for many, offering hope and better outcomes. Today, when breast cancer is detected at its earliest stages, the five-year relative survival rate stands at an impressive 99%, a testament to the power of clinical research. Let’s explore the advancements, methodologies, and impact of breast cancer clinical trials in shaping innovative treatment solutions.
A Closer Look at Breast Cancer Clinical Trials
At the heart of these advances are clinical trials, which play a pivotal role in discovering new ways to treat and manage breast cancer. By facilitating the development of groundbreaking treatments and improving existing therapies, clinical trials are integral to understanding the disease’s diverse forms. These studies not only offer patients access to innovative therapies that may not yet be widely available but also provide researchers with critical insights into the safety and efficacy of new treatment options.
At Lambda Therapeutic Research, we are committed to advancing breast cancer treatment through collaboration with global pharmaceutical and biotech partners. Clinical trials are not just about numbers and data; they are about people—patients, families, and caregivers—working together with scientists to bring about real, meaningful change. Every advancement brings us closer to more effective treatments. At Lambda, we’re honored to be part of that journey.
Oncology Excellence: A Proven Track Record
At Lambda & Novum, our commitment to advancing cancer treatment is reflected in our extensive experience in oncology clinical trials. With a strong portfolio that includes over 265 clinical trials spanning 15+ therapeutic areas, oncology remains a cornerstone of our expertise.
65+
Oncology Trials
6000+
Patients
900+
Global Sites
Lambda has established a solid track record in breast cancer clinical trials, conducting over 20+ studies in various indications. These include some of the most challenging forms of breast cancer, such as metastatic and triple-negative breast cancer (TNBC). Our experience extends enrolling over 2000 patients at 350 sites, reflecting our ability to manage large, complex trials efficiently while maintaining the highest standards of patient care and data integrity.
Our end-to-end capabilities—ranging from medical imaging to pharmacovigilance, biostatistics, and bioanalytical services—enable us to deliver comprehensive solutions for our clients. By ensuring high standards of quality and regulatory compliance, we consistently achieve robust, reliable trial results. Our successful regulatory submissions to the USFDA, EMA, and ANVISA underscore our deep understanding of global regulatory frameworks and our proficiency in navigating the complexities of the approval process. We also have extensive experience in biosimilar development, particularly with Trastuzumab and Pertuzumab—two key therapies in breast cancer treatment.
Optimizing Breast Cancer Trials:
Strategic Site Selection
Selecting the right clinical trial sites is crucial for the success of breast cancer clinical trials. We prioritize this process, focusing on experienced investigators and site staff well-versed in clinical oncology, especially in treating breast cancer. These carefully chosen sites ensure optimal data collection and a smoother trial experience for recruited patients.
Streamlining Recruitment & Retention
Enhancing trial success, we employ patient-centric initiatives and care coordinators, addressing barriers for a supportive participant experience. Recruitment and retention challenges are effectively tackled through these coordinators’ close work with participants, leading to improved patient outcomes and better data collection.
Innovative Trial Protocols
Innovation is at the heart of our trial protocols, ensuring a patient-centric experience. We design innovative and patient-friendly protocols that enhance the trial journey. By incorporating the latest advancements and considering the unique needs of breast cancer patients, we strive for improved outcomes and seamless data collection.
Transform Your Oncology Trials with Our Proven Expertise
Explore Our Success Stories:
Leverage Lambda & Novum’s extensive experience & proven track record to accelerate your Oncology clinical trials. Get in touch with our team of experts.
About Lambda
Lambda & Novum delivers comprehensive, end-to-end clinical research services to the innovator, biotech, and generic pharmaceutical industries worldwide. With a strong global presence in India, the USA, Canada, the UK, Spain and Poland, we bring specialized expertise to every project. Our focus on secure IT infrastructure and automation ensures timely project delivery and strict adherence to international regulatory standards. Lambda’s exemplary regulatory track record includes over 60 successful inspections and audits by esteemed authorities, including the USFDA, EMEA, MHRA, EU member states, and other global regulatory bodies, in the past five years.
Lambda’s commitment to excellence has garnered significant recognition, including the ‘Best Indian CRO’ award from Frost & Sullivan (USA) and the ‘Great Indian Workplace’ title from UBS Transformance. Recent accolades include the ‘Regulatory Excellence’ Award at the CPhI Pharma Awards 2023 and the ‘Industry Partner of the Year’ Award at the Global Generics & Biosimilar Awards 2023.
